Immunotherapeutic Approaches to Biliary Cancer

Urvi A. Shah, Amara G. Nandikolla, Lakshmi Rajdev

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Biliary tract cancers (BTCs) are rare aggressive neoplasms with a poor prognosis and a median survival of less than 1 year in the locally advanced or metastatic setting. Among the few patients who undergo curative resection the recurrence rates are high. About 90% of patients are detected at advanced stages, and systemic chemotherapy is the mainstay of their treatment. The treatment options for these patients are limited and multiple modalities of therapy from targeted therapy to immunotherapy and combination therapies (immunotherapy, targeted therapy, and chemotherapy) have been tested in this disease. Targeted therapies have failed to show a survival benefit. The deregulation of the immune system plays a significant role in the pathogenesis of BTCs. Therefore, immunotherapy, especially, immune checkpoint inhibitors hold great promise for this group of cancers. Numerous trials of immunotherapy in BTC are currently ongoing. In this review, we will discuss the available data and evidence for immunotherapy in BTC.

Original languageEnglish (US)
Article number44
JournalCurrent Treatment Options in Oncology
Volume18
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Biliary Tract Neoplasms
Immunotherapy
Therapeutics
Drug Therapy
Survival
Immune System
Neoplasms
Recurrence

Keywords

  • Biliary tract cancer
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Immune checkpoint inhibitors
  • Immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Immunotherapeutic Approaches to Biliary Cancer. / Shah, Urvi A.; Nandikolla, Amara G.; Rajdev, Lakshmi.

In: Current Treatment Options in Oncology, Vol. 18, No. 7, 44, 01.07.2017.

Research output: Contribution to journalReview article

Shah, Urvi A. ; Nandikolla, Amara G. ; Rajdev, Lakshmi. / Immunotherapeutic Approaches to Biliary Cancer. In: Current Treatment Options in Oncology. 2017 ; Vol. 18, No. 7.
@article{fdcbcb5c84a042c4a337380ccebcd070,
title = "Immunotherapeutic Approaches to Biliary Cancer",
abstract = "Biliary tract cancers (BTCs) are rare aggressive neoplasms with a poor prognosis and a median survival of less than 1 year in the locally advanced or metastatic setting. Among the few patients who undergo curative resection the recurrence rates are high. About 90{\%} of patients are detected at advanced stages, and systemic chemotherapy is the mainstay of their treatment. The treatment options for these patients are limited and multiple modalities of therapy from targeted therapy to immunotherapy and combination therapies (immunotherapy, targeted therapy, and chemotherapy) have been tested in this disease. Targeted therapies have failed to show a survival benefit. The deregulation of the immune system plays a significant role in the pathogenesis of BTCs. Therefore, immunotherapy, especially, immune checkpoint inhibitors hold great promise for this group of cancers. Numerous trials of immunotherapy in BTC are currently ongoing. In this review, we will discuss the available data and evidence for immunotherapy in BTC.",
keywords = "Biliary tract cancer, Cholangiocarcinoma, Gallbladder cancer, Immune checkpoint inhibitors, Immunotherapy",
author = "Shah, {Urvi A.} and Nandikolla, {Amara G.} and Lakshmi Rajdev",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s11864-017-0486-9",
language = "English (US)",
volume = "18",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Immunotherapeutic Approaches to Biliary Cancer

AU - Shah, Urvi A.

AU - Nandikolla, Amara G.

AU - Rajdev, Lakshmi

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Biliary tract cancers (BTCs) are rare aggressive neoplasms with a poor prognosis and a median survival of less than 1 year in the locally advanced or metastatic setting. Among the few patients who undergo curative resection the recurrence rates are high. About 90% of patients are detected at advanced stages, and systemic chemotherapy is the mainstay of their treatment. The treatment options for these patients are limited and multiple modalities of therapy from targeted therapy to immunotherapy and combination therapies (immunotherapy, targeted therapy, and chemotherapy) have been tested in this disease. Targeted therapies have failed to show a survival benefit. The deregulation of the immune system plays a significant role in the pathogenesis of BTCs. Therefore, immunotherapy, especially, immune checkpoint inhibitors hold great promise for this group of cancers. Numerous trials of immunotherapy in BTC are currently ongoing. In this review, we will discuss the available data and evidence for immunotherapy in BTC.

AB - Biliary tract cancers (BTCs) are rare aggressive neoplasms with a poor prognosis and a median survival of less than 1 year in the locally advanced or metastatic setting. Among the few patients who undergo curative resection the recurrence rates are high. About 90% of patients are detected at advanced stages, and systemic chemotherapy is the mainstay of their treatment. The treatment options for these patients are limited and multiple modalities of therapy from targeted therapy to immunotherapy and combination therapies (immunotherapy, targeted therapy, and chemotherapy) have been tested in this disease. Targeted therapies have failed to show a survival benefit. The deregulation of the immune system plays a significant role in the pathogenesis of BTCs. Therefore, immunotherapy, especially, immune checkpoint inhibitors hold great promise for this group of cancers. Numerous trials of immunotherapy in BTC are currently ongoing. In this review, we will discuss the available data and evidence for immunotherapy in BTC.

KW - Biliary tract cancer

KW - Cholangiocarcinoma

KW - Gallbladder cancer

KW - Immune checkpoint inhibitors

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85021625996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021625996&partnerID=8YFLogxK

U2 - 10.1007/s11864-017-0486-9

DO - 10.1007/s11864-017-0486-9

M3 - Review article

C2 - 28660602

AN - SCOPUS:85021625996

VL - 18

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 7

M1 - 44

ER -